H
Hui Liu
Researcher at University of Hong Kong
Publications - 23
Citations - 488
Hui Liu is an academic researcher from University of Hong Kong. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 217 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Hong Yang,Hui Liu,Yuping Chen,Chengchu Zhu,Wentao Fang,Zhentao Yu,Weimin Mao,Jiaqing Xiang,Yongtao Han,Zhijian Chen,Haihua Yang,Jiaming Wang,Qingsong Pang,Xiao Zheng,Huanjun Yang,Tao Li,Florian Lordick,Xavier B. D’Journo,Robert J. Cerfolio,Robert J. Korst,Nuria M. Novoa,Scott J. Swanson,Alessandro Brunelli,Mahmoud Ismail,Hiran C. Fernando,Xu Zhang,Qun Li,Geng Wang,Baofu Chen,Teng Mao,Min Kong,Xufeng Guo,Ting Lin,Mengzhong Liu,Jianhua Fu +34 more
TL;DR: This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.
Journal ArticleDOI
Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes
Daquan Wang,Xu Zhang,Hui Liu,Bo Qiu,Song Ran Liu,Chaojie Zheng,Jia-Ling Fu,Yiwen Mo,NaiBin Chen,Rui Zhou,Chu Chu,FangJie Liu,JinYu Guo,Yin Zhou,Yun Zhou,Wei Fan +15 more
TL;DR: The texture analysis indicated that PTs in the S-DFM group were more heterogeneous in FDG uptake than those in the F-DFm group, which suggested a potential benefit from immunotherapy, while PTs on the other hand seemed to be more homogenous in terms of [18F]FDG uptake.
Journal ArticleDOI
Efficacy of thymosin α1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).
FangJie Liu,Bo Qiu,Yu Xi,Yi-Feng Luo,Qiao-Ming Luo,Ying-Jia Wu,NaiBin Chen,Rui Zhou,JinYu Guo,Qingping Wu,Mai Chou Her Xiong,Hui Liu +11 more
TL;DR: In this article , the efficacy of thymosin α1 in management of radiation pneumonitis (RP) in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with concurrent chemoradiotherapy (CCRT) was evaluated.
Journal ArticleDOI
CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment
NaiBin Chen,M. Xiong,Rui Zhou,Yin Zhou,Bo Qiu,Yi-Feng Luo,Chu Chu,Qiwen Li,Bin Wang,Hai Hang Jiang,JinYu Guo,K. Peng,Chuanmiao Xie,Hui Liu +13 more
TL;DR: In this article , an integrated feature selection and model training approach using support vector machine combined with genetic algorithm was performed to predict 3-year overall survival (OS) in non-small cell lung cancer patients.
Journal ArticleDOI
Gut microbiome is associated with the response to Chemoradiotherapy in Patients with Non-small cell lung Cancer.
Bo Qiu,Yu Xi,FangJie Liu,Ying Li,Xinqiang Xie,JinYu Guo,SuPing Guo,Ying-Jia Wu,Lei Wu,Tingting Liang,Yu Fei Ding,Jumei Zhang,Qingping Wu,Hui Liu +13 more
TL;DR: In this article , the authors explore the dynamic change of gut microbiota and its predictive role in progression-free survival (PFS) in non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT).